1. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. (16th September 2022) Authors: Denton, Christopher P; Goh, Nicole S; Humphries, Stephen M; Maher, Toby M; Spiera, Robert; Devaraj, Anand; Ho, Lawrence; Stock, Christian; Erhardt, Elvira; Alves, Margarida; Wells, Athol U Journal: Rheumatology Issue: Volume 62:Number 5(2023) Page Start: 1870 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. (31st May 2022) Authors: Kreuter, Michael; Hoffmann-Vold, Anna-Maria; Matucci-Cerinic, Marco; Saketkoo, Lesley Ann; Highland, Kristin B; Wilson, Hilary; Alves, Margarida; Erhardt, Elvira; Schoof, Nils; Maher, Toby M Journal: Rheumatology Issue: Volume 62:Number SI(2023) Page Start: SI43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Nintedanib in children and adolescents with fibrosing interstitial lung diseases. Issue 2 (2nd February 2023) Authors: Deterding, Robin; Young, Lisa R.; DeBoer, Emily M.; Warburton, David; Cunningham, Steven; Schwerk, Nicolaus; Flaherty, Kevin R.; Brown, Kevin K.; Dumistracel, Mihaela; Erhardt, Elvira; Bertulis, Julia; Gahlemann, Martina; Stowasser, Susanne; Griese, Matthias Journal: European respiratory journal Issue: Volume 61:Issue 2(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗